Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes

J Gen Virol. 2021 Apr;102(4):001578. doi: 10.1099/jgv.0.001578.

Abstract

Infectious SARS-CoV-2 can be recovered from the oral cavities and saliva of COVID-19 patients with potential implications for disease transmission. Reducing viral load in patient saliva using antiviral mouthwashes may therefore have a role as a control measure in limiting virus spread, particularly in dental settings. Here, the efficacy of SARS-CoV-2 inactivation by seven commercially available mouthwashes with a range of active ingredients were evaluated in vitro. We demonstrate ≥4.1 to ≥5.5 log10 reduction in SARS-CoV-2 titre following a 1 min treatment with commercially available mouthwashes containing 0.01-0.02 % stabilised hypochlorous acid or 0.58 % povidone iodine, and non-specialist mouthwashes with both alcohol-based and alcohol-free formulations designed for home use. In contrast, products containing 1.5 % hydrogen peroxide or 0.2 % chlorhexidine gluconate were ineffective against SARS-CoV-2 in these tests. This study contributes to the growing body of evidence surrounding virucidal efficacy of mouthwashes/oral rinses against SARS-CoV-2, and has important applications in reducing risk associated with aerosol generating procedures in dentistry and potentially for infection control more widely.

Keywords: COVID-19; SARS-CoV-2; coronavirus; inactivation; mouthwash; oral rinse.

Publication types

  • Comparative Study

MeSH terms

  • Antiviral Agents / pharmacology*
  • COVID-19 / prevention & control
  • COVID-19 / transmission
  • Cell Survival / drug effects
  • Humans
  • Mouth / virology
  • Mouthwashes / pharmacology*
  • SARS-CoV-2 / drug effects*
  • Viral Load / drug effects
  • Virus Inactivation / drug effects*

Substances

  • Antiviral Agents
  • Mouthwashes